Journal Article

DKFZ-2019-02050

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Schlenk, R. F. (First author)DKFZ* ; Weber, D. ; Herr, W. ; Wulf, G. ; Salih, H. R. ; Derigs, H. G. ; Kuendgen, A. ; Ringhoffer, M. ; Hertenstein, B. ; Martens, U. M. ; Grießhammer, M. ; Bernhard, H. ; Krauter, J. ; Girschikofsky, M. ; Wolf, D. ; Lange, E. ; Westermann, J. ; Koller, E. ; Kremers, S. ; Wattad, M. ; Heuser, M. ; Thol, F. ; Göhring, G. ; Haase, D. ; Teleanu, V. ; Gaidzik, V. ; Benner, A.DKFZ* ; Döhner, K. ; Ganser, A. ; Paschka, P. ; Döhner, H.

2019
Springer Nature London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41375-019-0395-y

Abstract: Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

---

Contributing Institute(s):

1. Biostatistik (C060)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2019

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 10 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---